ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO352

Leucine-Rich a-2-Glycoprotein 1 Predicts Cardiovascular Diseases in ESRD Patients

Session Information

Category: Hypertension and CVD

  • 1402 Hypertension and CVD: Clinical, Outcomes, and Trials

Author

  • Yang, Feng-Jung, National Taiwan University Hospital Yulin Branch, Douliu, Taiwan
Background

Plasma Leucine-Rich a-2-Glycoprotein 1 leucine rich α-2 glycoprotein (LRG-1) as a novel serum biomarker for various inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Patients with end-stage renal disease (ESRD) are associated with several health-related adverse outcomes including inflammation, atherosclerosis and premature mortality in individuals. Whether level of Plasma Leucine-Rich a-2-Glycoprotein 1may associate with the clinical status of hemodialysis patients is unknown.

Methods

The immunity in ESRD study (iESRD) recruited 169 hemodialysis patients from southern Taiwan. By history taking and detailed chart reviews, baseline co-morbidities were recorded. Peripheral blood was sampled before hemodialysis session and processed immediately. Plasma levels of LRG1 and high-sensitivity C reactive protein were determined by ELISA. Peripheral blood monocyte and T cell differentiation subsets were determined by multicolor flow cytometry.

Results

Among these patients, 100% were LRG-1-seropositive. In the univariate analysis, log level of LRGwas independently associated with the existence of cardiovascular diseases including stroke and peripheral arterial occlusive disease (OR=111.9 95% CI=2.3-5283.3, p=0.016). In a multivariate-adjusted logistic regression model, log level of LRG was independently associated with the existence of cardiovascular diseases including stroke and peripheral arterial occlusive disease (OR=150.9 95% CI=2.3-9684.8, p=0.018) afteradjusting for gender, hemoglobin, DM, hypertension and hs-CRP. Level of LRG-1 positively correlated with both IL-6, CRP and WBC, indicating the accumulation of these cytokines participate in the progression of atherosclerosis.

Conclusion

LRG-1positively correlates with the existence of cardiovascular diseases in ESRD patients. Role of LRG-1 and the associated inflammation response should be further investigated in the pathogenesis of atherosclerosis in this patient population.